Oct 2026· Genetics and Molecular Biology· Vol 49· 0 citations· 120 references
Medicine
TL;DR
The historical development of mRNA delivery into human cells is revisited and the emergence of mRNA as a gene-therapy approach is discussed, emphasizing how mRNA-based technologies have become powerful tools for studying gene function and developing next-generation precision therapies.
Abstract
Abstract For nearly 50 years, scientists have sought to exploit messenger RNA (mRNA) as a therapeutic tool, overcoming major challenges related to instability, delivery, and inflammatory reactions. A major breakthrough came with the incorporation of modified nucleosides, particularly pseudouridine, during in vitro mRNA synthesis, which markedly improved stability, translation efficiency, and tolerability. The clinical success of mRNA technology was demonstrated in 2020 with the development of highly effective and safe COVID-19 vaccines, administered to over a billion individuals worldwide. These achievements inaugurated a new era in molecular medicine. In this review, we revisit the historical development of mRNA delivery into human cells and discuss the emergence of mRNA as a gene-therapy approach. In fact, beyond vaccination, mRNA platforms are rapidly expanding toward protein replacement therapies for genetic disorders and innovative strategies for cancer treatment. We summarize advances in synthetic mRNA design and optimization, delivery vehicles, and administration strategies that enable therapeutic applications. Finally, we highlight current limitations, technological challenges, and future opportunities, emphasizing how mRNA-based technologies have become powerful tools for studying gene function and developing next-generation precision therapies.
The rapid clinical validation of messenger RNA (RNA) during the COVID-19 pandemic has catalyzed a shift from traditional vaccine development toward a versatile, programmable therapeutic platform. This review provides a comprehensive analysis of the mRNA landscape, moving beyond historical milestones to critically evalu...
Utkarsh Sharma, Vishal Pandey, Hrishika Gupta et al.· Current pharmaceutical desig...· 0 citations
Gene therapy offers a fundamental approach to treating genetic disorders, malignant tumors, and refractory chronic diseases by directly modifying or replacing defective genes at the molecular level. Driven by policy support, increased investment, and technological innovation, China has achieved remarkable progress in a...
Jun-Shu Li, Yun Deng, Jin-Hu Ma et al.· Human Gene Therapy· 0 citations
circRNA-based cancer vaccines and in vivo chimeric antigen receptor T (CAR-T) cell immunotherapies have been documented successively, but the issue of circRNA immunogenicity remains unresolved.
Xin-Yue Wang, Sheng-Nan She, Chi Zhang et al.· Molecular Therapy: Nucleic A...· 0 citations
Small interfering RNA (siRNA) and messenger RNA (mRNA) therapeutics represent transformative approaches in precision pharmacology, enabling targeted gene silencing and protein expression, respectively. This review provides a comprehensive analysis of their molecular mechanisms, delivery strategies, clinical application...
Ritu Dahiya, A. Singh, Pooja Mathur et al.· Current Gene Therapy· 0 citations
Since the widespread use of mRNA-based COVID-19 vaccines, significant progress has also been made in mRNA cancer vaccines. Currently, mRNA cancer vaccines represent one of the most promising treatments for advanced tumors, with several candidates in clinical trials. Compared with traditional treatment methods, mRNA can...
A multidimensional framework is proposed in which gene therapy platforms are evaluated according to three intrinsic properties—genetic precision, temporal control, and dosage tunability—while delivery, clinical maturity, and disease context act as major translational constraints.
Jared Wieland, P. Jackson, William Penrod et al.· Cells· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.